Conference abstract
Seroprevalence of HIV amongst diabetes and healthy controls in Cameroon
Pan African Medical Journal - Conference Proceedings. 2023:19(38).23
Nov 2023.
doi: 10.11604/pamj-cp.2023.19.38.1934
Archived on: 23 Nov 2023
Contact the corresponding author
Keywords: HIV, prevalence, diabetes, Cameroon
Poster
Seroprevalence of HIV amongst diabetes and healthy controls in Cameroon
Arnaud Ndi1,2,&, Jean Claude Katte2,3, Sylvain Zemsi2, Magellan Guewo-Fokeng2,3,4, Joelle Tambekou-Sobngwi2, Eugene Sobngwi1,2,5
1National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon, 2RSD institute, Yaoundé, Cameroon, 3Laboratory of Metabolism and Molecular Medicine, Biotechnology Center, University of Yaoundé 1, Yaoundé, Cameroon, 4Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 5Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
&Corresponding author
Introduction: human Immunodeficiency virus (HIV), still represents an overwhelming proportion of the disease burden, with a dramatic impact on individuals, households, and countries’ economies. The greatest burden of the disease is in developing countries. The burden of diabetes mellitus is rapidly increasing in sub-Saharan Africa. Cameroon currently has a prevalence of HIV which stands at 3.8% in the adult general population. The burden of HIV in a disease-specific group such as diabetes is still unknown. We therefore aim to investigate the seroprevalence of HIV infection in a sub-population of patients with type 2 diabetes.
Methods: we carried out a cross-sectional study on 825 adult T2DM patients and 819 matched healthy controls. Immunochromatographic rapid tests for qualitative detection of antibodies specific to HIV 1 and 2 were used to ascertain the serological status. ELISA techniques were used to confirm cases of seropositivity obtained after the immunochromatographic test.
Results: female subjects constituted the majority of subjects with diabetes; 541 representing 65.6% of the subjects with diabetes. The mean age of the subjects with diabetes was 57.9 ± 10.5 years. The median duration of diabetes was 4[1-10] years. The seroprevalence of HIV in the subjects with diabetes was 8.9% while that of the healthy controls was 3.4%. Overall, the HIV infection rate was higher in female than in male subjects in both study groups.
Conclusion: the prevalence of HIV infection in the control group reflects the national prevalence in the adult general population. The prevalence of HIV in the diabetes subject population was almost twice the prevalence in the control group. These findings may serve as a framework for the planning and distribution of healthcare services within the subgroup of the diabetes patient population in Cameroon.
Seroprevalence of HIV amongst diabetes and healthy controls in Cameroon
Arnaud Ndi1,2,&, Jean Claude Katte2,3, Sylvain Zemsi2, Magellan Guewo-Fokeng2,3,4, Joelle Tambekou-Sobngwi2, Eugene Sobngwi1,2,5
1National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon, 2RSD institute, Yaoundé, Cameroon, 3Laboratory of Metabolism and Molecular Medicine, Biotechnology Center, University of Yaoundé 1, Yaoundé, Cameroon, 4Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 5Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
&Corresponding author
Introduction: human Immunodeficiency virus (HIV), still represents an overwhelming proportion of the disease burden, with a dramatic impact on individuals, households, and countries’ economies. The greatest burden of the disease is in developing countries. The burden of diabetes mellitus is rapidly increasing in sub-Saharan Africa. Cameroon currently has a prevalence of HIV which stands at 3.8% in the adult general population. The burden of HIV in a disease-specific group such as diabetes is still unknown. We therefore aim to investigate the seroprevalence of HIV infection in a sub-population of patients with type 2 diabetes.
Methods: we carried out a cross-sectional study on 825 adult T2DM patients and 819 matched healthy controls. Immunochromatographic rapid tests for qualitative detection of antibodies specific to HIV 1 and 2 were used to ascertain the serological status. ELISA techniques were used to confirm cases of seropositivity obtained after the immunochromatographic test.
Results: female subjects constituted the majority of subjects with diabetes; 541 representing 65.6% of the subjects with diabetes. The mean age of the subjects with diabetes was 57.9 ± 10.5 years. The median duration of diabetes was 4[1-10] years. The seroprevalence of HIV in the subjects with diabetes was 8.9% while that of the healthy controls was 3.4%. Overall, the HIV infection rate was higher in female than in male subjects in both study groups.
Conclusion: the prevalence of HIV infection in the control group reflects the national prevalence in the adult general population. The prevalence of HIV in the diabetes subject population was almost twice the prevalence in the control group. These findings may serve as a framework for the planning and distribution of healthcare services within the subgroup of the diabetes patient population in Cameroon.
